FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386008178> ?p ?o ?g. }

• W4386008178 endingPage "e8270611" @default.
• W4386008178 startingPage "e8270611" @default.
• W4386008178 abstract "Background: Acute lymphoblastic leukemia(ALL) is increasingly recognized as a disease with significant genetic heterogeneity. The JAK-STAT signaling pathway is an intracellular mechanism stimulated by cytokine, which is involved in a series of physiological processes, including cell proliferation, differentiation, apoptosis, immunomodulation, etc. STAT5, as a crucial activated transcription factor, plays a critical role in transformation of progenitor B cells. The dysfunction of STAT5 can promote various tumorigenesis. The insight that JAK/STAT system activation is pervasive in B cell malignancies suggests novel therapeutic approaches. Aims: We conducted a study to explore the relationship between STAT5 expression and the prognosis of B-ALL, and may allow the refinement of risk stratification and treatment for this disease. Patients may benefit from risk stratification on the basis of STAT5 expression at diagnosis. Methods: We have examined a cohort of 184 ALL patients enrolled between January 2018 and December 2021 from Nanfang Hospital. STAT5 expression was detected by flow cytometry and its clinical effect was assessed by Kaplan-Meier curves. Prognostic factors for patient were estimated by Cox regression method. Results: A subgroup of 113 patients (61.1%) showed low STAT5 expression, whereas 71 patients (38.9%) displayed high STAT5 expression levels. The other clinical characteristics including gender, age and WBC counts were not significantly different between the two groups. High expression was significantly associated with longer overall survival, with a median survival in the high expression group of 3.13 years(95% CI: 1.49 to not reached) and was not reached for low expression group(p=0.0042). The median EFS was 0.857 years(95% CI, 0.717-2.257 years) in the high expression group compared with 4.32 years(95% CI: 2.15 to not reached). The same trends were found in cumulative incidence of relapse. Based upon data above, Accordingly, cytoplasmic STAT5 ex-pression may have prognostic implication. We evaluated the prognostic significance of STAT5 high expression group in PDT-ALL-2016. Prognostic factors were evaluated by univariate Cox regression. This method identified a survival benefit in patients with high cytoplasmic STAT5 expression (HR=2.01, p=0.005 in OS,HR=1.99,p＜0.001) in addition to other prognostic factors, including age, WBC, CNSL, immunophenotype, Ph positivity,karyotype,IKZF1deletion,CD20 expression, MRD1/2/3 and MRD remission. Multivariate analysis indicated that high STAT5 expression remained a significant prognostic factor with respect to overall survival (HR=2.07, p=0.014) while MRD remission remained significant(HR=0.45,p=0.012). Likewise, in the EFS analysis, only STAT5 expression and MRD remission remained significant predictors of EFS (HR=2.03,p=0.003;HR=0.47,p=0.005).These results suggest that changes in the STAT5 expression have independent prognostic significance and cannot be replaced by Ph positivity. Summary/Conclusion: Our results showed that high expression of STAT5 has been independently linked to poor prognosis in ALL. The detection of STAT5 phosphorylation could be introduced in the routine clinical workout for ALL patients.Keywords: Acute lymphoblastic leukemia, B cell acute lymphoblastic leukemia, STAT5, Prognosis" @default.
• W4386008178 created "2023-08-20" @default.
• W4386008178 creator A5018626132 @default.
• W4386008178 creator A5032457247 @default.
• W4386008178 creator A5034407018 @default.
• W4386008178 creator A5047757729 @default.
• W4386008178 creator A5048404300 @default.
• W4386008178 creator A5053027274 @default.
• W4386008178 creator A5079631458 @default.
• W4386008178 date "2023-08-01" @default.
• W4386008178 modified "2023-10-17" @default.
• W4386008178 title "P403: HIGH EXPRESSION OF STAT5 INDICATES POOR PROGNOSIS IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIA" @default.
• W4386008178 doi "https://doi.org/10.1097/01.hs9.0000968520.82706.11" @default.
• W4386008178 hasPublicationYear "2023" @default.
• W4386008178 type Work @default.
• W4386008178 citedByCount "0" @default.
• W4386008178 crossrefType "journal-article" @default.
• W4386008178 hasAuthorship W4386008178A5018626132 @default.
• W4386008178 hasAuthorship W4386008178A5032457247 @default.
• W4386008178 hasAuthorship W4386008178A5034407018 @default.
• W4386008178 hasAuthorship W4386008178A5047757729 @default.
• W4386008178 hasAuthorship W4386008178A5048404300 @default.
• W4386008178 hasAuthorship W4386008178A5053027274 @default.
• W4386008178 hasAuthorship W4386008178A5079631458 @default.
• W4386008178 hasBestOaLocation W43860081781 @default.
• W4386008178 hasConcept C126322002 @default.
• W4386008178 hasConcept C143998085 @default.
• W4386008178 hasConcept C170493617 @default.
• W4386008178 hasConcept C190283241 @default.
• W4386008178 hasConcept C203014093 @default.
• W4386008178 hasConcept C2778277574 @default.
• W4386008178 hasConcept C2778461978 @default.
• W4386008178 hasConcept C2778923194 @default.
• W4386008178 hasConcept C2779391668 @default.
• W4386008178 hasConcept C502942594 @default.
• W4386008178 hasConcept C50382708 @default.
• W4386008178 hasConcept C54355233 @default.
• W4386008178 hasConcept C553184892 @default.
• W4386008178 hasConcept C71924100 @default.
• W4386008178 hasConcept C72563966 @default.
• W4386008178 hasConcept C86803240 @default.
• W4386008178 hasConceptScore W4386008178C126322002 @default.
• W4386008178 hasConceptScore W4386008178C143998085 @default.
• W4386008178 hasConceptScore W4386008178C170493617 @default.
• W4386008178 hasConceptScore W4386008178C190283241 @default.
• W4386008178 hasConceptScore W4386008178C203014093 @default.
• W4386008178 hasConceptScore W4386008178C2778277574 @default.
• W4386008178 hasConceptScore W4386008178C2778461978 @default.
• W4386008178 hasConceptScore W4386008178C2778923194 @default.
• W4386008178 hasConceptScore W4386008178C2779391668 @default.
• W4386008178 hasConceptScore W4386008178C502942594 @default.
• W4386008178 hasConceptScore W4386008178C50382708 @default.
• W4386008178 hasConceptScore W4386008178C54355233 @default.
• W4386008178 hasConceptScore W4386008178C553184892 @default.
• W4386008178 hasConceptScore W4386008178C71924100 @default.
• W4386008178 hasConceptScore W4386008178C72563966 @default.
• W4386008178 hasConceptScore W4386008178C86803240 @default.
• W4386008178 hasIssue "S3" @default.
• W4386008178 hasLocation W43860081781 @default.
• W4386008178 hasLocation W43860081782 @default.
• W4386008178 hasLocation W43860081783 @default.
• W4386008178 hasOpenAccess W4386008178 @default.
• W4386008178 hasPrimaryLocation W43860081781 @default.
• W4386008178 hasRelatedWork W2039312480 @default.
• W4386008178 hasRelatedWork W2041205265 @default.
• W4386008178 hasRelatedWork W2144888252 @default.
• W4386008178 hasRelatedWork W2162516128 @default.
• W4386008178 hasRelatedWork W2374987808 @default.
• W4386008178 hasRelatedWork W2775174560 @default.
• W4386008178 hasRelatedWork W2916246606 @default.
• W4386008178 hasRelatedWork W2917410143 @default.
• W4386008178 hasRelatedWork W3087149089 @default.
• W4386008178 hasRelatedWork W2004445097 @default.
• W4386008178 hasVolume "7" @default.
• W4386008178 isParatext "false" @default.
• W4386008178 isRetracted "false" @default.
• W4386008178 workType "article" @default.